The ongoing Arimoclomol Clinical Trial for sIBM continues to generate a lot of questions from our community. As part of our commitment to providing the latest information on research and clinical trials, we asked Dr. Mazen Dimachkie, Principal Investigator for the Phase II/III Arimoclomol Studies and Professor of Neurology and Director of the Neuromuscular Division at University of Kansas Medical Center, if he would provide us with an update.
Dr. Dimachkie was gracious enough to take the time to talk with Jerry Williams and Lynn Wilson this week. The presentation and Q&A were based on the sIBM community feedback and questions about the trial.
About Mazen M. Dimachkie, MD, FAAN, FANA
Professor of Neurology & Director of Neuromuscular Division
Executive Vice Chairman & Vice Chairman for Research Program, Department of Neurology
University of Kansas Medical Center, Kansas City, Kansas, USA
Mazen M. Dimachkie, MD, FAAN, FANA, received his undergraduate and medical degrees from the American University of Beirut in Lebanon before completing 2 years of Internal Medicine training at Saint Agnes Hospital in Baltimore, Maryland. Dr. Dimachkie then completed a residency in Neurology at UT-Houston from July 1, 1990 to June 30, 1993 and fellowship in electromyography & Neuromuscular Disease from July 1, 1993 to June 30, 1994, both at The University of Texas Health Science Center at Houston (UT-Houston). He is ABPN board-certified in Neurology, Clinical Neurophysiology, and Neuromuscular Medicine and holds a UCNS certificate in Clinical Neuromuscular Pathology. He was elected as fellow member of the American Academy of Neurology and of the American Neurological Association. After being on faculty at the UT-Houston Neurology Department 1995-2007, he was recruited to lead the prolific neuromuscular Section and now Division at the University of Kansas Medical Center in Kansas City (KUMC). He is now Professor of Neurology, director of the Neuromuscular Division at the KUMC, director of the Neuromuscular Medicine Fellowship and Executive Vice Chairman & Vice Chairman for Research at the Neurology Department. As the director of KUMC Neuromuscular Research, he manages one of the busiest neuromuscular clinical trials units in North America. He leads and participates in a wide variety of federally-funded neuromuscular research studies and industry-sponsored studies, nationally and internationally. He has authored or co-authored more than 400 abstracts, articles, and book chapters. He is a frequently invited lecturer in the fields of myositis, myasthenia gravis, ALS, neuropathies and other neuromuscular topics. Dr. Dimachkie serves on the executive committee of the Muscle Study Group, and serves on the MSABs of the Myasthenia Gravis Foundation of America and The Myositis Association.
Learn how clinical trials work
Watch “Clinical Trials 101” to learn more about how clinical trials work. This will be helpful information when tuning in for the upcoming session.